<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="abstract" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Innov Aging</journal-id>
<journal-id journal-id-type="iso-abbrev">Innov Aging</journal-id>
<journal-id journal-id-type="publisher-id">geroni</journal-id>
<journal-title-group>
<journal-title>Innovation in Aging</journal-title>
</journal-title-group>
<issn pub-type="epub">2399-5300</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
<publisher-loc>US</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmc">6243781</article-id>
<article-id pub-id-type="doi">10.1093/geroni/igx004.932</article-id>
<article-id pub-id-type="publisher-id">igx004.932</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Abstracts</subject>
<subj-group subj-group-type="category-toc-heading">
<subject>Session LB610 (Poster): Late Breaker Poster Session 1</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>STRUCTURAL STUDIES OF ATASE1 AND ATASE2: NOVEL TARGETS FOR ALZHEIMER’S DISEASE AND AGING </article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Farrugia</surname>
<given-names>M.A.</given-names>
</name>
<xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feig</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="AF0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Puglielli</surname>
<given-names>L.</given-names>
</name>
<xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>
<institution>Medicine, University of Wisconsin-Madison</institution>, <addr-line>Madison, Wisconsin</addr-line>,</aff>
<aff id="AF0002">
<label>2</label>
<institution>Eli Lilly</institution>, <addr-line>Indianapolis, Indiana</addr-line>,</aff>
<aff id="AF0003">
<label>3</label>
<institution>Michigan State University</institution>, <addr-line>East Lansing, Michigan</addr-line></aff>
<pub-date pub-type="collection">
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date iso-8601-date="2017-06-30" pub-type="epub">
<day>30</day>
<month>6</month>
<year>2017</year>
</pub-date>
<volume>1</volume>
<issue>Suppl 1</issue>
<issue-title>Program Abstracts from the 21st International Association of Gerontology and Geriatrics (IAGG) World Congress</issue-title>
<fpage>253</fpage>
<lpage>254</lpage>
<permissions>
<copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America.</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<self-uri xlink:href="igx004.932.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>The endoplasmic reticulum (ER) acetylation machinery includes AT-1/SLC33A1, a membrane transporter that transfers acetyl-CoA from the cytosol into the ER lumen, and ATase1 and ATase2, two ER-based Nε-lysine acetyltransferases. Mutations, genetic duplications, and increased gene dosage affecting the ER-based acetylation machinery have been associated with a familial form of spastic paraplegia, developmental delay and premature death, autism spectrum disorder with intellectual disability and progeria-like features, and late-onset Alzheimer’s disease (AD). Importantly, AT-1/SLC33A1 is upregulated in p44+/+ mice, a mouse model of progeria, and mice overexpressing AT-1/SLC33A1 display a progeria-like phenotype. Finally, genetic or biochemical inhibition of the ER acetylation machinery can rescue AD in the mouse. At the mechanistic level, the ER acetylation machinery has been linked to maintenance of protein homeostasis within the secretory pathway. As such, ATase1 and ATase2 are currently active targets for therapeutics. Here, we used structural biochemistry and site-directed mutagenesis approaches to identify essential features of the enzymes, including the acetyl-CoA and the peptidyl-lysine binding pockets. We also explored the likely binding orientations of 31 inhibitors known to affect ATase activity in vitro. Computational docking of the compounds using AutodockVINA identified 9 inhibitors with strong (&lt; -8 kcal/mol) binding and binding pockets which differ between ATase1 and ATase2 in both overall area and residues predicted to be involved in docking. Varied concentrations of these compounds were used to treat H4 neuroglioma cells to observe their effect on autophagy and using electron microscopy and Western blot analysis of known autophagic markers.</p>
</abstract>
<counts>
<page-count count="2"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>